A chitosan-carrageenan polyelectrolyte complex (PEC) was prepared by salt induced impeding of polyplex formation method and was encapsulated with bovine serum albumin (BSA) to study the potential to be tailored to the pH responsive oral delivery of protein drugs. The FTIR spectra showed the successful formation of the PEC under the experimental condition. The release kinetics of BSA from the PEC was studied in the simulated gastrointestinal fluids with and without digestive enzymes. The prepared PEC showed the nature of pH-sensitivity. A typical controlled release of BSA from the PEC (180?μg of BSA from 3?mg of PEC) was obtained in the simulated intestinal fluid (SIF, pH 7.5), which was due to the significant swelling and disintegration of PEC, but little amount of BSA was released (11?μg of BSA from 3?mg of PEC) in the simulated gastric fluid (SGF, pH 1.2), confirming acidic stability of the prepared PEC. The presence of digestive enzymes was found not to affect the response of PEC to ambient pH value, but to speed up the release of BSA from carriers. 1. Introduction With the rapid development in biotechnology and recombinant technology, more and more therapeutic peptides and proteins have been produced as drugs at commercial scale. Among various routes for administrating the drugs, oral route is preferred due to its high levels of patient acceptance and long term compliance [1]. Moreover, the dosage forms can be formulated with relative ease and are manufactured without sterile conditions [2]. However, this delivery route faces ineffectiveness for the peptide and protein drugs because the drugs can be easily hydrolyzed by the extreme acidity in the stomach and proteolytic enzymes in the gastrointestinal (GI) tract. The penetration barrier also prevents them from crossing the intestinal and then basal membranes for entry into the blood [3]. To improve the oral bioavailability from less than 1% to at least 30–50% for a polypeptide drug delivery through the GI tract has attracted intensive research [4]. Polyelectrolyte complexes (PEC) are formed by the ionic interactions as ionically cross-linked networks when two oppositely charged polyelectrolytes bind each other in an aqueous solution [5]. The net charge fixed on the complex, which is an important factor determining the swelling and the induced volume change of the PEC, is affected by pH value of ambient solution due to the variation in the degree of ionization of functional groups [6]. Thus, the nature of highly pH-sensitive swelling brings PEC to the application of oral drug delivery [7, 8] because
References
[1]
M. Morishita and N. A. Peppas, “Is the oral route possible for peptide and protein drug delivery?” Drug Discovery Today, vol. 11, no. 19-20, pp. 905–910, 2006.
[2]
N. N. Salama, N. D. Eddington, and A. Fasano, “Tight junction modulation and its relationship to drug delivery,” Advanced Drug Delivery Reviews, vol. 58, no. 1, pp. 15–28, 2006.
[3]
V. H. L. Lee and A. Yamamoto, “Penetration and enzymatic barriers to peptide and protein absorption,” Advanced Drug Delivery Reviews, vol. 4, no. 2, pp. 171–207, 1989.
[4]
V. H. L. Lee, D. Satish, M. George, and R. Werner, Oral Route of Protein and Peptide Drug Delivery, Marcel Dekker, New York, NY, USA, 1991.
[5]
A. S. Michaels and R. G. Miekka, “Polycation-polyanion complexes: preparation and properties of poly-(vinylbenzyltrimethylammonium) poly-(styrenesulfonate),” Journal of Physical Chemistry, vol. 65, no. 10, pp. 1765–1773, 1961.
[6]
E. Vasheghani-Farahani, J. H. Vera, D. G. Cooper, and M. E. Weber, “Swelling of ionic gels in electrolyte solutions,” Industrial and Engineering Chemistry Research, vol. 29, no. 4, pp. 554–560, 1990.
[7]
H. Brondsted and J. Kopecek, “Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation,” Pharmaceutical Research, vol. 9, no. 12, pp. 1540–1545, 1992.
[8]
H. Brondsted and J. Kopecek, “pH-Sensitive hydrogels—charateristics and potential in drug delivery,” ACS Symposium Series, vol. 480, pp. 285–304, 1992.
[9]
C. Tapia, Z. Escobar, E. Costa et al., “Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem clorhydrate release systems,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 57, no. 1, pp. 65–75, 2004.
[10]
S. Torrado, P. Prada, P. M. De La Torre, and S. Torrado, “Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention,” Biomaterials, vol. 25, no. 5, pp. 917–923, 2004.
[11]
V. Crescenzi, G. Paradossi, P. Desideri et al., “New hydrogels based on carbohydrate and on carbohydrate-synthetic polymer networks,” Polymer Gels and Networks, vol. 5, no. 3, pp. 225–239, 1997.
[12]
T. Sakiyama, H. Takata, T. Toga, and K. Nakanishi, “pH-sensitive shrinking of a dextran sulfate/chitosan complex gel and its promotion effect on the release of polymeric substances,” Journal of Applied Polymer Science, vol. 81, no. 3, pp. 667–674, 2001.
[13]
F. Chellat, M. Tabrizian, S. Dumitriu et al., “In vitro and in vivo biocompatibility of chitosan-xanthan polyionic complex,” Journal of Biomedical Materials Research, vol. 51, no. 1, pp. 107–116, 2000.
[14]
Q. Zhang, L. Liu, L. Ren, and F. Wang, “Preparation and characterization of collagen-chitosan composites,” Journal of Applied Polymer Science, vol. 64, no. 11, pp. 2127–2130, 1997.
[15]
T. Sakiyama, C. H. Chu, T. Fujii, and T. Yano, “Preparation of a polyelectrolyte complex gel from chitosan and K-carrageenan and its pH-sensitive swelling,” Journal of Applied Polymer Science, vol. 50, no. 11, pp. 2021–2025, 1993.
[16]
J. Berger, M. Reist, J. M. Mayer, O. Felt, and R. Gurny, “Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 57, no. 1, pp. 35–52, 2004.
[17]
C. H. Chu, T. Sakiyama, and T. Yano, “pH-Sensitive swelling of a polyelectrolyte complex gel prepared from xanthan and chitosan,” Bioscience, Biotechnology, and Biochemistry, vol. 59, no. 4, pp. 717–719, 1995.
[18]
P. He, S. S. Davis, and L. Illum, “In vitro evaluation of the mucoadhesive properties of chitosan microspheres,” International Journal of Pharmaceutics, vol. 166, no. 1, pp. 75–88, 1998.
[19]
B. J. Aungst, “Intestinal permeation enhancers,” Journal of Pharmaceutical Sciences, vol. 89, no. 4, pp. 429–442, 2000.
[20]
C. Tapia, V. Corbalán, E. Costa, M. N. Gai, and M. Yazdani-Pedram, “Study of the release mechanism of diltiazem hydrochloride from matrices bases on chitosan-alginate and chitosan-carrageenan mixtures,” Biomacromolecules, vol. 6, no. 5, pp. 2389–2395, 2005.
[21]
A. Bartkowiak and D. Hunkeler, “Carrageenan-oligochitosan microcapsules: optimization of the formation process,” Colloids and Surfaces B, vol. 21, no. 4, pp. 285–298, 2001.
[22]
C. A. Kienzle-Sterzer, D. Rodriguez-Sanchez, and C. K. Rha, “Flow behavior of a cationic biopolymer: chitosan,” Polymer Bulletin, vol. 13, no. 1, pp. 1–6, 1985.
[23]
US Pharmacopoeia, 23rd edition, 1995.
[24]
Q. Gan and T. Wang, “Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release,” Colloids and Surfaces B, vol. 59, no. 1, pp. 24–34, 2007.